%0 Journal Article
%T 不同激素状态的HER2阳性晚期乳腺癌复发转移特征及生存分析
%A 任玉琳
%A 佟仲生
%A 张丽
%J 肿瘤防治研究
%D 2019
%R 10.3971/j.issn.1000-8578.2019.18.0962
%X 摘要 目的 探讨不同HR状态的HER2阳性晚期乳腺癌患者的复发转移特征、预后及解救曲妥珠单抗治疗疗效的差异。方法 回顾性分析237名HER2阳性晚期乳腺癌患者的临床病理学资料，根据HR状态分为HR+/HER2+组和HR-/HER2+组，对两组间临床病理学特征、复发转移特点、预后及解救曲妥珠单抗治疗疗效进行分析比较。结果 与HR-/HER2+相比，HR+/HER2+多为绝经前患者，临床分期以Ⅰ~Ⅱ期为主，T分期更早，较少发生腋窝淋巴结转移。在总体复发转移部位上HR+/HER2+者更易发生骨转移，较少发生肺转移。HR+/HER2+组中位总生存时间34（5~102）月，HR-/HER2+组为29（3~70）月，两组间差异有统计学意义。接受解救曲妥珠单抗联合化疗的患者，ER<50%者达PR者占68.6%，ER≥50%者占46.2%，差异有统计学意义（P=0.037）。多因素分析结果显示ER状态是HR+/HER2+晚期乳腺癌的独立预后因素；肝转移、解救抗HER2靶向治疗是HR-/HER2+晚期乳腺癌的独立预后因素。结论 与HR-/HER2+患者相比，HR+/HER2+患者多发生骨转移，较少发生肺转移；预后较好；ER阳性细胞数所占比例较高的患者解救曲妥珠单抗治疗疗效较差
%K A Predictor of Risk and Prognosis of Breast Cancer
%K Tanshinone ⅡA Enhances Chemosensitivity of Breast Cancer Cells to Doxorubicin and Related Mechanism
%K In Situ Hybridization Status of 568 Cases of HER2 Equivocal Breast Cancer
%K Apatinib Suppresses Proliferation and Induced Apoptosis of Human Breast Cancer Cell Line MDA-MB-231 Through Glycolytic Inhibition
%K Progress of Whole Exon Sequencing in Pathogenesis and Diagnosis of Breast Cancer
%K Feedback Activation of STAT3 Confers Resistance of HER2-positive Breast Cancer Cells to Lapatinib
%K Influence of NRP-1 Monoclonal Antibody on Growth of Breast Cancer Xenografts in Nude Mouse
%K Expression of Circular RNA ciRS-7 and Its Effect on Invasion and Migration of Triplenegative reast Cancer Cells
%K Correlation Between 18F-FDG PET/CT SUVmax and Clinicopathological Features
%K Neoadjuvant Chemotherapy Response in Invasive Ductal Breast Carcinoma Patients
%U http://www.zlfzyj.com/CN/abstract/abstract9314.shtml